Pharma industry must focus on R&D: Eco Survey

/2 min read

ADVERTISEMENT

The Economic Survey 2024-25 says on a global pedestal, India has successfully established itself as one of the top 20 medical device markets.
Pharma industry must focus on R&D: Eco Survey
At present, the nation holds a 1.5% share of the global market in the industry. Credits: Getty Images

The Economic Survey 2024-25 highlights the rapid growth of India’s medical devices industry, with a strong 15% CAGR (compound annual growth rate). At present, the nation holds a 1.5% share of the global market in the industry and ranks fourth in market size in Asia, trailing behind Japan, China and South Korea.

On a global pedestal, India has successfully established itself as one of the top 20 medical device markets.

India is making remarkable advancements in cell and gene therapy. In October 2023, the Central Drugs Standard Control Organisation (CDSO) approved the nation’s first indigenously developed CAR-T cell therapy. This therapy is claimed to be the most affordable globally. The CAR-T Cell therapy has been developed by Prof. Rahul Purwar and his team at the BSBE Department, IIT Bombay in close association with Tata Memorial Centre and ImmunoACT. 

To speed up the availability of newer drugs such as gene therapies, orphan drugs, drugs representing significant therapeutic advantage in the country, the CDSO has notified the US, the UK, Japan, Australia, Canada and the European Union, enabling waiver of local clinical trial for new drugs that are already approved and marketed in the notified countries.

fortune magazine cover
Fortune India Latest Edition is Out Now!
Netflix’s India Decade

January 2026

Netflix, which has been in India for a decade, has successfully struck a balance between high-class premium content and pricing that attracts a range of customers. Find out how the U.S. streaming giant evolved in India, plus an exclusive interview with CEO Ted Sarandos. Also read about the Best Investments for 2026, and how rising growth and easing inflation will come in handy for finance minister Nirmala Sitharaman as she prepares Budget 2026.

Read Now

“The overall pharma landscape of India points towards a need to focus on innovation, new drug development and biopharmaceuticals, as R&D spending still lags behind global leaders,” it adds.

Among the top five pharmaceutical producers, the US topped with a strong 4.7% QoQ growth in Q3 2024, followed by Japan at 1.4% and China recorded 0.9%. However, Switzerland stumbled with a 2.1% decline and India experienced a slight drop of 1.2%, as noted by UNIDO (United Nations Industrial Development Organisation).

Explore the world of business like never before with the Fortune India app. From breaking news to in-depth features, experience it all in one place. Download Now